Skip to content

Merck & Co., Inc.

Follow

13F filer, CIK 310158, RAHWAY, NJ

Merck & Co., Inc. reported $820,348,090 across 13 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13. Its ten largest share positions make up 99.87% of the portfolio.

Accepted , ingested 13F-HR 0000310158-26-000249

Period
2026-09-30
Reported value
$820M
Holdings
13
Top 10 weight
99.87%
New
0
Sold out
0

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0000310158-26-000249, largest first. % of portfolio is the value over $820,348,090, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,308,190 shares; 2025Q1: 2,308,190 shares; 2025Q2: 2,308,190 shares; 2025Q3: 2,308,190 shares; 2025Q4: 2,308,190 shares; 2026Q1: 2,308,190 shares; 2026Q2: 2,308,190 shares; 2026Q3: 2,308,190 shares 2,308,190$444M54.18%0Timeline
PSNLPERSONALIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 14,044,943 shares; 2025Q1: 14,044,943 shares; 2025Q2: 14,044,943 shares; 2025Q3: 14,044,943 shares; 2025Q4: 14,044,943 shares; 2026Q1: 14,044,943 shares; 2026Q2: 14,044,943 shares; 2026Q3: 14,044,943 shares 14,044,943$229M27.87%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 772,165 shares; 2025Q1: 772,165 shares; 2025Q2: 772,165 shares; 2025Q3: 772,165 shares; 2025Q4: 772,165 shares; 2026Q1: 772,165 shares; 2026Q2: 772,165 shares; 2026Q3: 772,165 shares 772,165$86.3M10.52%0Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 952,844 shares; 2026Q2: 952,844 shares; 2026Q3: 952,844 shares 952,844$18.6M2.26%0Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,666,666 shares; 2026Q2: 1,666,666 shares; 2026Q3: 1,666,666 shares 1,666,666$13.4M1.63%0Timeline
TRDAENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,739,768 shares; 2026Q3: 1,739,768 shares 1,739,768$11M1.35%0Timeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,545,719 shares; 2025Q1: 3,545,719 shares; 2025Q2: 3,545,719 shares; 2025Q3: 3,545,719 shares; 2025Q4: 3,545,719 shares; 2026Q1: 3,545,719 shares; 2026Q2: 3,545,719 shares; 2026Q3: 3,545,719 shares 3,545,719$6.56M0.8%0Timeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 272,351 shares; 2026Q3: 272,351 shares 272,351$4.39M0.53%0Timeline
EVAXEVAXION ASQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,214,126 shares; 2026Q3: 1,214,126 shares 1,214,126$3.98M0.49%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 93,414 shares; 2025Q1: 93,414 shares; 2025Q2: 93,414 shares; 2025Q3: 93,414 shares; 2025Q4: 93,414 shares; 2026Q1: 93,414 shares; 2026Q2: 93,414 shares; 2026Q3: 93,414 shares 93,414$1.92M0.23%0Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 105,982 shares; 2026Q2: 105,982 shares; 2026Q3: 105,982 shares 105,982$959K0.12%0Timeline
HURATUHURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,950 shares; 2025Q3: 13,950 shares; 2025Q4: 13,950 shares; 2026Q1: 19,445 shares; 2026Q2: 19,445 shares; 2026Q3: 19,445 shares 19,445$40.8K<0.01%0Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 10,027 shares; 2025Q1: 10,027 shares; 2025Q2: 10,027 shares; 2025Q3: 10,027 shares; 2025Q4: 10,027 shares; 2026Q1: 10,027 shares; 2026Q2: 10,027 shares; 2026Q3: 10,027 shares 10,027$35.7K<0.01%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000310158-26-000249 base2026-11-13